ArticleFrontiers in oncology2021

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.

Chiaki Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.